Figure 2.
Panel A: Cumulative probability of starting an immunomodulator from time of anti- tumour necrosis factor [TNF] monotherapy initiation in the overall population [n = 350]. Panel B: Cumulative probability of remaining on combination therapy from time of immunomodulator initiation in the 53 patients.